Eric Leip
Overview
Explore the profile of Eric Leip including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gambacorti-Passerini C, Cortes J, Lipton J, Kantarjian H, Kim D, Schafhausen P, et al.
Haematologica
. 2018 May;
103(8):1298-1307.
PMID: 29773593
Bosutinib is a Src/Abl tyrosine kinase inhibitor indicated for adults with newly-diagnosed Philadelphia positive chronic myeloid leukemia or with resistant/intolerant disease. We report the final results of a phase I/II...
12.
Cortes J, Gambacorti-Passerini C, Deininger M, Mauro M, Chuah C, Kim D, et al.
J Clin Oncol
. 2017 Nov;
36(3):231-237.
PMID: 29091516
Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy. We assessed the efficacy...
13.
Cortes J, Gambacorti-Passerini C, Kim D, Kantarjian H, Lipton J, Lahoti A, et al.
Clin Lymphoma Myeloma Leuk
. 2017 Aug;
17(10):684-695.e6.
PMID: 28807791
Background: The purpose of the study was to assess renal function in patients with Philadelphia chromosome-positive leukemias receiving bosutinib or imatinib. Patients And Methods: Patients received first-line bosutinib (n =...
14.
Cortes J, Khoury H, Kantarjian H, Lipton J, Kim D, Schafhausen P, et al.
Am J Hematol
. 2016 Aug;
91(12):1206-1214.
PMID: 27531525
Bosutinib is an Src/Abl tyrosine kinase inhibitor (TKI) indicated for adults with Ph+ chronic myeloid leukemia (CML) resistant/intolerant to prior TKIs. This long-term update of an ongoing phase 1/2 study...
15.
Cortes J, Khoury H, Kantarjian H, Brummendorf T, Mauro M, Matczak E, et al.
Am J Hematol
. 2016 Mar;
91(6):606-16.
PMID: 26971533
Vascular and cardiac safety during tyrosine kinase inhibitor (TKI) therapy is an emerging issue. We evaluated vascular/cardiac toxicities associated with long-term bosutinib treatment for Philadelphia chromosome-positive (Ph+) leukemia based on...
16.
Brummendorf T, Cortes J, Khoury H, Kantarjian H, Kim D, Schafhausen P, et al.
Br J Haematol
. 2015 Nov;
172(1):97-110.
PMID: 26537529
The dual SRC/ABL1 tyrosine kinase inhibitor bosutinib is indicated for adults with Ph+ chronic myeloid leukaemia (CML) resistant/intolerant to prior therapy. This analysis of an ongoing phase 1/2 study (NCT00261846)...
17.
Gambacorti-Passerini C, Kantarjian H, Kim D, Khoury H, Turkina A, Brummendorf T, et al.
Am J Hematol
. 2015 Jun;
90(9):755-68.
PMID: 26040495
Long-term efficacy and safety of bosutinib (≥4 years follow-up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure...
18.
Gambacorti-Passerini C, Brummendorf T, Kim D, Turkina A, Masszi T, Assouline S, et al.
Am J Hematol
. 2014 Apr;
89(7):732-42.
PMID: 24711212
Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2-year...
19.
Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, et al.
Oncologist
. 2014 Mar;
19(4):348-9.
PMID: 24674874
Background: Endocrine therapy resistance in hormone receptor-positive (HR+) breast cancer (BC) may involve crosstalk between HRs and growth factor signaling pathways. We evaluated bosutinib, a dual Src/Abl tyrosine kinase inhibitor...
20.
Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, et al.
Oncologist
. 2014 Mar;
19(4):346-7.
PMID: 24674873
Background: Bosutinib is an oral, selective Src/Abl tyrosine kinase inhibitor with activity in breast cancer (BC). We evaluated bosutinib plus exemestane as second-line therapy in previously treated hormone receptor-positive (HR+)...